Novo Nordisk stock crashed Friday after the firm's next-generation weight-loss drug missed expectations in a highly ...

Novo Nordisk A/S’s failure to meet its own bar for success on a next-generation obesity shot shows the danger of promising ...

Investors are warned against buying TTEC stock due to poor performance, dividend suspension, and operational challenges amid ...

The Advanced Research Projects Agency for Health (ARPA-H) awarded TigaTx up to $33.5 million in funding. Tessera Therapeutics ...

Investors and analysts had eagerly awaited this data as a test of Novo’s case that it has a strong pipeline of drugs to ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

IES Holdings has shown remarkable growth, with sales increasing more than fivefold over ten years, driven by organic growth ...

The FDA removed Eli Lilly’s LLY tirzepatide injection products from the drug shortage list after determining that Lilly’s ...

STORY: Novo Nordisk saw as much as $125 billion wiped off its market value on Friday (Dec 20).Investors sold off after a ...

Shares in the company dived after a new anti-obesity treatment missed expectations in a study, denting its chances of becoming the company's next blockbuster weight loss drug. Nvidia's takeover of ...

The all-cash deal has involved Novo Holdings acquiring Catalent for $16.5bn, including debt. It will then sell three of ...

Shares of Novo Nordisk (NYSE:NVO) plummeted over 19% in premarket trading Friday after the results from its phase 3 trial of ...